(1888PressRelease)
April 25, 2009 - The report will be presented by Biovitrum's CEO Martin Nicklasson and CFO Göran Arvidson. The presentation will be held in English and webcasted live.
Time: Tuesday, April 28, 2009 at 2 p.m. (CET)
Venue: Grand Hotel, Scholanderska rummet, Stockholm
Coffee will be served
The report will be published at 8.30 a.m. (CET) the same day.
Participation:
To participate, please register to Mikael Nilimaa on mikael.nilimaa ( @ ) zoomvision dot se or by telephone +46 702 699 322 dot
Internet broadcast:
The presentation will be broadcasted live on Internet, April 28 at 2 p.m. (CET): www.biovitrum.com.
Telephone conference call:
You may also participate with questions by telephone.
Dial-in numbers:
SE: +46 8 505 202 70
UK: + 44 208 817 9301
US: +1 718 354 1226
The presentation material will be published on our web site after the meeting as will the archived web cast, please go to: www.biovitrum.com.
Welcome!
Erik Kinnman, VP Investor Relations
Phone: +46 8 697 21 50, erik.kinnman ( @ ) biovitrum dot com
About Biovitrum
Biovitrum is a Swedish pharmaceutical company. The company markets a range of specialist pharmaceuticals internationally. Using its expertise and experience Biovitrum takes scientific innovation all the way to the market and to specialist indication patients with significant medical need. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within our prioritized areas of hemophilia, inflammation/autoimmune diseases and malabsorption. The company has revenues of approximately SEK 1.1 billion and around 400 employees. It is listed on the OMX Nordic Exchange in Stockholm. For more information go to www.biovitrum.com.
###
